Treatment of RA-ASCs with high/moderate molecular weight adiponectin only was found to considerably upregulate the secretion of the soluble factors IL-1RA, PGE2, TGF-β, IL-6, IL-8, and VEGF, however, it did not greatly impact the weak immunosuppressive effects of RA-ASCs on PHA-activated PBMCs [250]. The gene discussed is CXCL8; the disease is rheumatoid arthritis.